Phenomenon or Process
WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects
BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns
WHO Approves First Mpox Diagnostic Test for Emergency Use: Expanding Global Access to Mpox Testing
WHO, mpox diagnostic test, emergency use, Abbott Molecular, Alinity m MPXV assay, global health emergency, public health efforts
FDA Authorizes Novavax’s Updated COVID-19 Vaccine for Emergency Use
Novavax COVID-19 Vaccine, FDA Authorization, Emergency Use, Protein-Based Vaccine, JN.1 Variant
Novavax’s Updated COVID-19 Vaccine Receives FDA Emergency Use Authorization
Novavax, COVID-19 vaccine, FDA, Emergency Use Authorization, protein-based vaccine, JN.1 variant
FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate
Invivyd, COVID-19, Pemgarda, Emergency Use Authorization, FDA, Immunocompromised, Variants
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.
Merck’s Ebola Vaccine Demonstrates 84% Effectiveness in Real-World Setting During DRC Outbreak
Ebola vaccine, Merck, Ervebo, effectiveness, real-world analysis, DRC outbreak, vaccination, public health.
Mpox Outbreak in Africa: Siga’s Tpoxx Antiviral Falls Short in Congo Study
mpox, Tpoxx, antiviral, Congo study, Africa outbreak, Siga, tecovirimat
Accelerating Sales of Eisai and Biogen’s Alzheimer’s Drug Leqembi in Japan
Leqembi, Alzheimer’s drug, Eisai, Biogen, Japan, sales acceleration
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms